Klein S, Fricke H J, Fricke B, Friedrich R, Illessy A, Schröder K D
Klinik und Poliklinik für Augenkrankheiten, Bereiches Medizin der Friedrich-Schiller-Universität, Jena.
Fortschr Ophthalmol. 1990;87(4):355-8.
In a search for alternative therapeutic methods other than corticosteroids and cytostatics, the effect of a dialyzable leukocyte extract (DLE), the antimetabolite 5-fluorouracil and the immunosuppressive agent cyclosporin A in corticosteroid-resistant idiopathic uveitis was studied. When DLE was administered to 26 patients who had uveitis forms with exogenous triggering (e.g., infection), as well as forms with an autoimmune background, there was a reduction in the number and duration of recurrences and a statistically proven prolongation of the inflammation-free intervals. This was particularly true in anterior and posterior uveitis and to a lesser extent in the intermediate form. No side effects were observed. 5-Fluorouracil, injected subconjunctivally, is indicated in intermediate uveitis with marked vitreous infiltration and beginning proliferation. Corneal erosion occurs relatively often. During treatment with cyclosporin A (low dose, 5 mg/kg of body weight per day), 14 of 17 patients (9 with intermediate uveitis, 6 with retinal vasculitis, 1 with sympathetic ophthalmia, 1 with panuveitis) showed improved results; in 2 cases the findings remained stationary and only 1 case had low-grade deterioration. If one takes into consideration the fact that in this patient any therapy would have failed, the results are convincing. This is particularly true of retinal vasculitis. There is no effect in cases of central hemorrhagic chorioretinopathy. So far, there have been no serious side effects.
为寻找除皮质类固醇和细胞抑制剂以外的其他治疗方法,研究了可透析白细胞提取物(DLE)、抗代谢物5-氟尿嘧啶及免疫抑制剂环孢素A对皮质类固醇抵抗性特发性葡萄膜炎的疗效。对26例患有外源性触发型葡萄膜炎(如感染)以及自身免疫背景型葡萄膜炎的患者给予DLE治疗后,复发次数和持续时间减少,无炎症间隔期在统计学上得到证实延长。这在前葡萄膜炎和后葡萄膜炎中尤为明显,在中间型葡萄膜炎中程度稍轻。未观察到副作用。结膜下注射5-氟尿嘧啶适用于伴有明显玻璃体浸润和开始增殖的中间型葡萄膜炎。角膜糜烂相对常见。在用环孢素A(低剂量,每天5mg/kg体重)治疗期间,17例患者中有14例(9例中间型葡萄膜炎、6例视网膜血管炎、1例交感性眼炎、1例全葡萄膜炎)病情改善;2例病情无变化,仅1例轻度恶化。如果考虑到该患者任何治疗都可能失败这一事实,结果令人信服。视网膜血管炎尤其如此。对中心性出血性脉络膜视网膜病变无效。到目前为止,尚未出现严重副作用。